The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immunological targeting of CD133 in recurrent glioblastoma: A multi-center phase I translational and clinical study of autologous CD133 dendritic cell immunotherapy.
 
Jeremy David Rudnick
Consulting or Advisory Role - Bristol-Myers Squibb; Novocure
Speakers' Bureau - Novocure
Research Funding - ImmunoCellular Therapeutics (Inst)
 
Karen L. Fink
Consulting or Advisory Role - Novocure
Speakers' Bureau - Genentech
 
Joseph C. Landolfi
Honoraria - Meridian Healthcare; Novocure
Consulting or Advisory Role - Novocure
 
James Markert
Employment - UAB Health System Foundation
Leadership - UAB Health System Foundation
Stock and Other Ownership Interests - Aettis; Catherex
Research Funding - Northwest Biotherapeutics
Patents, Royalties, Other Intellectual Property - UAB Research Foundation
Other Relationship - Catherex
 
David Eric Piccioni
No Relationships to Disclose
 
Michael J. Glantz
Honoraria - Sigma-Tau
Speakers' Bureau - Sigma-Tau
Research Funding - Abbvie (Inst); Cell Therapeutics (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); ImmunoCellular Therapeutics (Inst); Newlink Genetics (Inst); Orbus Therapeutics (Inst); RTOG (Inst); Sunovion (Inst); Tocagen (Inst); Triphase Accelerator Corp (Inst); Vascular Biogenics (Inst)
Other Relationship - Abbvie
 
Steven J. Swanson
Employment - ImmunoCellular Therapeutics
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - ImmunoCellular Therapeutics
 
Anthony Gringeri
Employment - ImmunoCellular Therapeutics
Leadership - ImmunoCellular Therapeutics
Stock and Other Ownership Interests - ImmunoCellular Therapeutics
 
John Yu
Employment - ImmunoCellular Therapeutics
Leadership - ImmunoCellular Therapeutics
Stock and Other Ownership Interests - ImmunoCellular Therapeutics
Consulting or Advisory Role - ImmunoCellular Therapeutics
Patents, Royalties, Other Intellectual Property - ImmunoCellular Therapeutics